Efficacy of gonadotropin-releasing hormone agonist (buserelin) in the treatment of endometriosis.
In a multicenter study, the efficacy of and tolerance of 6 months' intranasal gonadotropin-releasing hormone agonist (buserelin) treatment (300 micrograms x 3/day) on laparoscopically verified endometriosis was evaluated in 25 patients. At second-look laparoscopy at the end of medication, the mean endometriosis score had fallen by 82.2%. All endometriosis-associated symptoms and physical findings decreased or almost disappeared during buserelin administration. After discontinuing therapy, they showed a tendency to reappear, but nevertheless they were milder after one year of follow-up, than before treatment. Seven (54%) of the 13 women wishing pregnancy actually conceived. Vaginal irregular spotting bleedings during the first 2 months occurred in 7 patients. No patient withdrew from the trial because of side effects, although almost all women developed symptoms of estrogen deficiency (serum estradiol concentrations fell to menopausal levels).
Rönnberg
L
L
Department of Obstetrics and Gynecology, University Central Hospitals of Oulu, Finland.
Koskimies
A
A
Laatikainen
T
T
Ranta
T
T
Saastamoinen
J
J
D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006728:Hormones / Q000097:blood; D006801:Humans; D015337:Multicenter Studies as Topic; D011247:Pregnancy
D006728:Hormones; D002064:Buserelin